An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Niu, Yanqin ^a   Zhang, Limin ^a   Qiu, Huiling ^a   Wu, Yike ^a   Wang, Zhiwei ^b   Zai, Yujia ^b   Liu, Lin ^c   Qu, Junle ^a   Kang, Kang ^d   Gou, Deming ^a  

^a SHENZHEN UNIVERSITY   (China)

^b Shenzhen Sun Yat Sen Cardiovascular Hospital   (China)

^c OKLAHOMA STATE UNIVERSITY   (United States)

^d Shenzhen University School of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; POLYTHYMIDYLIC ACID; PRIMER DNA;

BLOOD; CELL LINE; COMPLICATION; CONGENITAL HEART MALFORMATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; HYPERTENSION, PULMONARY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CELL LINE; DNA PRIMERS; GENE EXPRESSION PROFILING; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS; POLY T; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84944224284     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15100     Document Type: Article

References (45)

1. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. cell 116, 281-297 (2004).
2. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531 (2004).
3. Lim, L. P., Glasner, M. E., Yekta, S., Burge, C. B. & Bartel, D. P. Vertebrate microRNA genes. Science 299, 1540-1540 (2003).
4. Bader, A. G., Brown, D. & Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 70, 7027-7030 (2010).
5. Bushati, N. & Cohen, S. M. microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175-205 (2007).
6. Chen, J.-F. et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233 (2005).
7. Croce, C. M. & Calin, G. A. miRNAs, cancer, and stem cell division. Cell 122, 6-7 (2005).
8. Di Masi, A. et al. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile. Cell Mol. Biol. 56, OL1299-1317 (2010).
9. Diakos, C. et al. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 116, 4885-4893 (2010).
10. Jensen, S. G. et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 12, 435 (2011).
11. Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009).
12. Wang, K. et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. P. Nat. A. Sci. 106, 4402-4407 (2009).
13. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. P. Nat. A. Sci. 105, 10513-10518 (2008).
14. Gupta, S. K., Bang, C. & Thum, T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ. Cardiovasc. Gene. 3, 484-488 (2010).
15. Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12, R90 (2010).
16. Toiyama, Y. et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 259, 735-743 (2014).
17. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Ccids Res. 33, e179-e179 (2005).
18. Jiang, J., Lee, E. J., Gusev, Y. & Schmittgen, T. D. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Ccids Res. 33, 5394-5403 (2005).
19. Reichenstein, I., Aizenberg, N., Goshen, M., Bentwich, Z. & Avni, Y. S. A novel qPCR assay for viral encoded microRNAs. J. Virol. methods 163, 323-328 (2010).
20. Design, R.-T. P. P. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques 39, 519-525 (2005).
21. Kang, K. et al. A novel real-time PCR assay of microRNAs using S-Poly (T), a specific oligo (dT) reverse transcription primer with excellent sensitivity and specificity. PloS one 7, e48536 (2012).
22. Burgos, K. L. et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 19, 712-722 (2013).
23. Rhodes, C. J. et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am. J. Resp. Crit. Care. 187, 294-302 (2013).
24. Wei, C. et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One 8, e64396 (2013).
25. Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R. & Grimminger, F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443-455 (2011).
26. Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009).
27. Landzberg, M. J. Congenital heart disease associated pulmonary arterial hypertension. Clin. Chest Med. 28, 243-253 (2007).
28. Camps, C. et al. miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348 (2008).
29. Mandegar, M. et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc. Res. 68, 75-103 (2004).
30. Zeng, Y. et al. MiR-20a regulates the PRKG1 gene by targeting its coding region in pulmonary arterial smooth muscle cells. FEBS Lett. 588, 4677-4685 (2014).
31. Zeng, Y. et al. MicroRNA-9 enhances the transactivation of nuclear factor of activated T cells by targeting KPNB1 and DYRK1B. Am. J. Physiol-Cell Ph. 308, C720-C728 (2015).
32. Courboulin, A. et al. Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 208, 535-548 (2011).
33. Caruso, P. et al. A role for miR-145 in pulmonary arterial hypertension evidence from mouse models and patient samples. Circ. Res. 111, 290-300 (2012).
34. Caruso, P. et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscl. Throm. Vas. 30, 716-723 (2010).
35. Grant, J. S. et al. Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. Pulm. Cir. 3, 840 (2013).
36. Qin, X. et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. P. Nat. Acad. Sci. 107, 3240-3244 (2010).
37. Sarkar, J. et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol-Lung C. 299, L861-L871 (2010).
38. Shanshan, L. et al. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem. J. 452, 281-291 (2013).
39. Cheng, Y. et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105, 158-166 (2009).
40. Mizuno, S. et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am. J. Physiol-Lung C. 300, L753-L761 (2011).
41. Guo, L. et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α 1C. Hypertension 59, 1006-1013 (2012).
42. Bockmeyer, C. L. et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J. Heart Lung Transpl. 31, 764-772 (2012).
43. Kim, J. et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 19, 74-82 (2013).
44. Kang, K. et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J. Biol. Chem. 288, 25414-25427 (2013).
45. Vinck, J. et al. MiR-223 Improves Experimental Pulmonary Arterial Hypertension. Circulation 130, A18653-A18653 (2014).